Building the operational layer for clinical trial samples.
Short-form thinking on how sponsors, CROs, and central labs can bring continuous visibility, cross-vendor reconciliation, and AI-native operations to biospecimen management.
The cost of not using SpeciGen: Time, Money, and Opportunity every clinical trial is losing.
The uncomfortable math on how biospecimen reconciliation quietly costs clinical trials more than any line item on the study budget. Scientist FTE on VLOOKUPs, missed samples caught at database lock, change orders every time your protocol amends, and your own data behind somebody else’s SLA.
How SpeciGen uses AI to speed up clinical trials.
Faster study setup, continuous reconciliation, earlier risk detection, less manual work. Where AI-native and agentic AI actually change the speed, cost, and accuracy of running a trial — and where deterministic rules and human judgment still lead.
One Portal Is Not the Whole Study.
A central lab portal shows you honestly what the central lab knows. It cannot show you the parts of your study that aren’t in the central lab. That gap is where cross-vendor reconciliation quietly lives.
The Dashboard Is Your Panel. Operational AI Flies the Plane.
Reporting tells you what happened. Operational intelligence tells you what’s happening — and what’s next. Clinical trials were never a spreadsheet-and-dashboard problem.
The AI Gap in Clinical Trials.
Every pharma company wants to become AI-first for clinical operations. Productivity copilots don’t change how trials run. Where AI should actually create value in sample management.